Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel

Rakhmad Hidayat, Alyssa Putri Mustika, Fhathia Avisha, Zlatikha Djuliannisaa, Dinisa Diah Winari, Ria Amiliah Putri, Heydi Marizky Lisman, Vandra Davin, Alvina Widhani, Muhammad Hafiz Aini, Meilisa Rahmadani, Novita Dwi Istanti, Astuti Giantini

Research output: Contribution to journalArticlepeer-review

Abstract

Facing the rising cases of with higher fatalities COVID-19, some countries decided to give the third dose of vaccine as a booster. As of 9 January 2022, 90.31% of health workers in Indonesia have received the third dose vaccine. This study aims to provide an evaluation of adverse events following immunization (AEFI) in a single center in Indonesia to form a basis for ensuring safety for booster administration nationally. A retrospective, cross-sectional study was conducted using an online survey. Demographic data, AEFI complaints, and factors influencing AEFIs were evaluated. In this study, there were a total of 311 subjects were gathered. The most common AEFI symptoms found at onset <24 h to 28 days were pain at the injection site, fever, shoulder pain, and headache. Most of the AEFI severity of <24 h to 28 days post-vaccination was grade 1 (reduced or uninterrupted daily activities). There was a significant correlation between AEFI and several factors, such as the history of drug allergy, exercise after vaccination, age, BMI < 25, history of symptoms after the first and second vaccinations, and history of COVID-19. There was no anaphylactic reaction in this study. Several AEFI should be considered for the third dose of COVID-19 vaccine administration.

Original languageEnglish
Article number877
JournalVaccines
Volume10
Issue number6
DOIs
Publication statusPublished - Jun 2022

Keywords

  • AEFI
  • booster vaccine
  • health workers
  • mRNA-based vaccine

Fingerprint

Dive into the research topics of 'Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel'. Together they form a unique fingerprint.

Cite this